Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||75%|
|1 Day Vol Adjusted Return||-0.5|
|1 Month Vol Adjusted Return||2.6|
|3 Month Vol Adjusted Return||-4.5|
|6 Month Vol Adjusted Return||-8.5|
|20 Days SMA Price ZScore||1.4|
|50 Days SMA Price ZScore||-0.0|
|12 -26 Days PPO||-1.0|
|1 Month Average Short Volume Ratio||44.6|
|1 Day Volume Change ZScore||-0.5|
|1 Month Daily Vol||4.7|
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Shares of Editas Medicine (NASDAQ: EDIT) were up 12.7% this week, as of Thursday's close, according to data provided by S&P Global Market Intelligence. It did so to improve its cash position, which as of the third quarter was listed at $478.5 million, enabling it to fund operations through 2025. The move further helps Editas' cash position and allows it to focus on its in-vivo gene-editing programs and promising blood therapies, including EDIT-301, used to treat transfusion-dependent beta thal...
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The mean of analysts' price targets for Editas (EDIT) points to a 72.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.
Editas Medicine Inc (NASDAQ: EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies to Shoreline Biosciences. Shoreline will also acquire Editas Medicine's preclinical gene-edited induced pluripotent stem cell (iPSC) derived natural killer cell (iNK) programs and manufacturing technologies. Shoreline will pay Editas Medicine an undisclosed upfront payment at the close of the transaction. Editas Medicine is eligible to
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies Economics to Editas Medicine to include upfront payment, and development and commercial milestone and royalty payments CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (
CRISPR could revolutionize the way we treat thousands of diseases. Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material, the Cleveland Clinic reported. Fortunately, CRISPR, or clustered regularly interspaced short palindromic repeats, has the potential to treat most, if not all of these illnesses. In fact, according to Interesting Engineering, “researchers have already identified DNA errors as the cause of nearly 7,000 diseases. Thank
Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.